Delving into the Latest Updates on SHR-1681 with Synapse

Overview

Basic Info

Drug Type

Biological products

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas

Neoplasms

Active Indication

Advanced Malignant Solid NeoplasmMalignant Solid Neoplasm

Inactive Indication-

Originator Organization

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Active Organization

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Shanghai Shengdi Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

Primary purpose: To evaluate the safety and tolerability of SHR-1681 in patients with advanced solid tumors and provide recommended doses for subsequent clinical studies. Secondary purpose: To evaluate the pharmacokinetic characteristics of SHR-1681 in subjects with advanced solid tumors and to evaluate the preliminary efficacy of SHR-1681.

Start Date21 Jan 2025

Sponsor / Collaborator

Shanghai Shengdi Pharmaceutical Co., Ltd.

[+1]

NCT06737731

/ RecruitingPhase 1/2

A Phase I/II, Multicenter, Open-Label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1681 for Injection in Patients With Malignant Solid Tumors

This study is an open-label, multicenter Phase I/II clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-1681 for injection in patients with advanced solid tumors.

Start Date21 Jan 2025

Sponsor / Collaborator

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

100 Clinical Results associated with SHR-1681

Login to view more data

100 Translational Medicine associated with SHR-1681

Login to view more data

100 Patents (Medical) associated with SHR-1681

Login to view more data

100 Deals associated with SHR-1681

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 2	China	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	21 Jan 2025
Malignant Solid Neoplasm	Phase 2	China	Shanghai Shengdi Pharmaceutical Co., Ltd.	21 Jan 2025